多发性骨髓瘤患者血清IL-6、CRP的临床意义  

Clinical significance of serum IL-6 and CRP in multiple myeloma patients

作　　者：季丽莉[1] 陈晨[1] 张雪皎[1] 王伟光[1] 程志祥[1] 袁玲[1] 魏征[1] 承璐雅[1] 庄静丽[1] 王志梅[1] 李锋[1] 邹善华[1] 刘澎[1] 

机构地区：[1]复旦大学附属中山医院血液科,上海200032

出　　处：《中国临床医学》2016年第3期337-340,共4页Chinese Journal of Clinical Medicine

基　　金：国家自然科学基金(81300381;81570123);上海市卫计委青年科研项目(20134y117)~~

摘　　要：目的:探讨白介素6(interleukin 6,IL-6)和C反应蛋白(C reactive protein,CRP)与多发性骨髓瘤(multiple myeloma,MM)患者分期的关系,及其在预判疗效方面的作用。方法:检测2015年1月1日至2016年1月31日复旦大学附属中山医院血液科收治的MM患者血清中IL-6、CRP水平,并分析不同DS分期、ISS分期以及化疗(4周期)效果的MM患者血清中IL-6、CRP水平的差异。结果:不同DS分期、ISS分期患者血清中CRP、IL-6水平的差异均无统计学意义。治疗高效组、中效组和无效组患者治疗前血清CRP水平的差异有统计学意义(P<0.05)。结论:CRP升高可能提示MM患者化疗疗效不佳,但IL-6水平不足以反映骨髓瘤IL-6信号通路状态。Objective：To explore the relationship between interleukin 6（IL-6）,C reactive protein（CRP）and the staging of multiple myeloma（MM）patients and their role in predicting efficacy.Methods：Serum IL-6 and CRP levels in MM patients admitted to the Department of Hematology,Zhongshan Hospital Affiliated to Fudan University,between January 1,2015 and January 31,2016 were reviewed and the differences of serum IL-6 and CRP levels in MM patients with different DS stages,ISS stages and chemotherapy efficacy（4circles）were analyzed.Results：There was no significant difference in serum IL-6 and CRP levels in the patients with different DS stages or ISS stages.There was statistical significance（P〈0.05）in serum CRP levels in the patients pre-treatment between the high-efficiency group,the medium-efficiency group,and the ineffective group.Conclusions：Elevated CRP might indicate poor efficacy of chemotherapy in MM patients,and IL-6 level is not enough to reflect the status of myeloma IL-6 signaling pathway.

关 键 词：多发性骨髓瘤 白介素6 C反应蛋白 

分 类 号：R856.5[医药卫生—航空、航天与航海医学]